🔎 Trials Near Me

Home › Quitting Smoking (Tobacco Use Disorder) › NCT05962229

Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

RecruitingPhase 1Healthy volunteers welcome

Who can join

Ages 21 to 65 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Healthy on the basis of medical history and limited physical examination.
* Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)

Exclusion Criteria:

* • Medications

  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
  * Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
  * Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
  * Any stimulant medications (example: Adderall) generally given for ADHD treatment.

    • Pregnancy
  * Pregnancy (self-reported and urine pregnancy test)
  * Breastfeeding (determined by self-report)
  * Women of childbearing potential must be using an acceptable method of contraception

    * Inability to read and write in English
    * A known propylene glycol/vegetable glycerin allergy
    * Uncomfortable with getting blood drawn

About the study

In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.

What is being tested

Sponsor: University of California, San Francisco · Participants: 18 · Started: Dec 6, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05962229

Locations in the U.S.

CaliforniaZuckerberg San Francisco General Hospital (ZSFG), San Francisco

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.